NASDAQ: AURA - Aura Biosciences, Inc.

六个月盈利: +16.5%
股息率: 0.00%
部门: Healthcare

促销时间表 Aura Biosciences, Inc.


关于公司 Aura Biosciences, Inc.

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for treating tumors of high unmet need in ocular and urologic oncology. It is developing AU-011, a VDC candidate for the treatment of primary choroidal melanoma that is in phase III clinical trial. The company also develops AU-011 for additional ocular oncology indications, including choroidal metastases and is in Phase 2 dose-escalation trial.

更多详情
The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.

IPO date 2021-10-29
ISIN US05153U1079
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.aurabiosciences.com
Цена ао 7.63
每日价格变化: -0.9512% (8.41)
每周价格变化: +1.59% (8.2)
每月价格变化: -7.44% (9)
3个月内价格变化: -7.75% (9.03)
六个月内的价格变化: +16.5% (7.15)
每年价格变化: -5.98% (8.86)
3年内价格变化: -43.56% (14.76)
5年内价格变化: 0% (8.33)
10年价格变化: 0% (8.33)
年初以来价格变化: -6.19% (8.88)

低估

姓名 意义 年级
P/S 0 0
P/BV 1.58 8
P/E 0 0
EV/EBITDA -4 0
全部的: 3.25

效率

姓名 意义 年级
ROA, % -29.96 0
ROE, % -33.83 0
全部的: 0

股息

姓名 意义 年级
Div yield, % 0 0
DSI 0 0
全部的: 0

责任

姓名 意义 年级
Debt/EBITDA -0.2337 10
全部的: 8.6

成长冲动

姓名 意义 年级
盈利能力 Revenue, % 0 0
盈利能力 Ebitda, % 254.64 10
盈利能力 EPS, % 10.83 2
全部的: 6.4

ETF 分享, % 本年盈利能力, % 股息, %
Range Cancer Therapeutics ETF 1.74943 47.24 0.11955
AltShares Event-Driven ETF 0.97581 9.61 1.21959
iShares Micro-Cap ETF 0.11218 17.09 1.54048
DBX ETF Trust - Xtrackers International Real Estate ETF 0.06228 -4.53 4.01983
Dimensional International Small Cap ETF 0.02439 5.69 3.34747
Avantis U.S Small Cap Equity ETF 0.02437 27.77 1.68271
FlexShares Morningstar Developed Markets ex-US Factor Tilt Index Fund 0.01698 5.17 3.85434
Vanguard Russell 2000 ETF 0.01 17.16 1.48801
ProShares UltraPro Russell2000 0.00959 89.82 1.47873
Avantis International Equity ETF 0.0028 6.46 3.80856
ProShares Hedge Replication ETF 0.0027 5.92 1.47892
Dimensional World ex U.S. Core Equity 2 ETF 0.00213 13.06 3.62488
Dimensional International Core Equity 2 ETF 0.002 6.52 3.69996
Dimensional International Core Equity Market ETF 0.00084 13.09 3.48343
Dimensional US Core Equity Market ETF 0.00066 30.98 1.40618
iShares Russell 3000 ETF 0.00056 24.83 1.43482
Dimensional U.S. Equity ETF 0.0004 31.53 1.3557
Dimensional U.S. Core Equity 2 ETF 0.00024 30.76 1.47098
Vanguard Russell 3000 ETF 0 31.87 1.43817



导师 职称 支付 出生年份
Dr. Elisabet de los Pinos Ph.D. Founder, CEO, President & Director 895.16k 1974 (51 年)
Ms. Julie B. Feder Chief Financial Officer 604.2k 1971 (54 年)
Dr. Mark Plavsic D.V.M., Ph.D. Chief Technology Officer N/A 1961 (64 年)
Mr. Patrick Nealon Senior Vice President of Clinical Development Operations N/A
Dr. Anthony Daniels M.D. Therapeutic Area Head of Ocular Oncology N/A
Dr. Richard Mountfield Ph.D. Senior Vice President of Regulatory Affairs & Quality N/A
Mr. Conor Kilroy General Counsel & Secretary N/A 1982 (43 年)
Dr. Jill J. Hopkins M.D. Chief Medical Officer & President of Research and Development N/A 1965 (60 年)

地址: United States, Boston. MA, 80 Guest Street - 在 Google 地图中打开, 打开 Yandex 地图
网站: https://www.aurabiosciences.com